Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artículo científico |
| Langue: | en |
| Publié: |
Natural product reports
2025
|
| Sujets: | |
| Accès en ligne: | https://pubmed.ncbi.nlm.nih.gov/39620500/ |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1868266272972603392 |
|---|---|
| author | Luesch, Hendrik Ellis, Emma K Chen, Qi-Yin Ratnayake, Ranjala |
| author_facet | Luesch, Hendrik Ellis, Emma K Chen, Qi-Yin Ratnayake, Ranjala Luesch, Hendrik Ellis, Emma K Chen, Qi-Yin Ratnayake, Ranjala |
| collection | PubMed - marine biology |
| contents | Progress in the discovery and development of anticancer agents from marine cyanobacteria. Luesch, Hendrik Ellis, Emma K Chen, Qi-Yin Ratnayake, Ranjala Cyanobacteria Antineoplastic Agents Humans Biological Products Drug Discovery Aquatic Organisms Molecular Structure Animals Depsipeptides Covering 2010-April 2024There have been tremendous new discoveries and developments since 2010 in anticancer research based on marine cyanobacteria. Marine cyanobacteria are prolific sources of anticancer natural products, including the tubulin agents dolastatins 10 and 15 which were originally isolated from a mollusk that feeds on cyanobacteria. Decades of research have culminated in the approval of six antibody-drug conjugates (ADCs) and many ongoing clinical trials. Antibody conjugation has been enabling for several natural products, particularly cyanobacterial cytotoxins. Targeting tubulin dynamics has been a major strategy, leading to the discovery of the gatorbulin scaffold, acting on a new pharmacological site. Cyanobacterial compounds with different mechanisms of action (MOA), targeting novel or validated targets in a range of organelles, also show promise as anticancer agents. Important advances include the development of compounds with novel MOA, including apratoxin and coibamide A analogues, modulating cotranslational translocation at the level of Sec61 in the endoplasmic reticulum, largazole and santacruzamate A targeting class I histone deacetylases, and proteasome inhibitors based on carmaphycins, resembling the approved drug carfilzomib. The pipeline extends with SERCA inhibitors, mitochondrial cytotoxins and membrane-targeting agents, which have not yet advanced clinically since the biology is less understood and selectivity concerns remain to be addressed. In addition, efforts have also focused on the identification of chemosensitizing and antimetastatic agents. The review covers the state of current knowledge of marine cyanobacteria as anticancer agents with a focus on the mechanism, target identification and potential for drug development. We highlight the importance of solving the supply problem through chemical synthesis as well as illuminating the biological activity and in-depth mechanistic studies to increase the value of cyanobacterial natural products to catalyze their development. |
| format | Artículo científico |
| id | pubmed_39620500 |
| institution | PubMed |
| language | en |
| publishDate | 2025 |
| publisher | Natural product reports |
| record_format | pubmed |
| spellingShingle | Progress in the discovery and development of anticancer agents from marine cyanobacteria. Luesch, Hendrik Ellis, Emma K Chen, Qi-Yin Ratnayake, Ranjala Cyanobacteria Antineoplastic Agents Humans Biological Products Drug Discovery Aquatic Organisms Molecular Structure Animals Depsipeptides Progress in the discovery and development of anticancer agents from marine cyanobacteria. Luesch, Hendrik Ellis, Emma K Chen, Qi-Yin Ratnayake, Ranjala Cyanobacteria Antineoplastic Agents Humans Biological Products Drug Discovery Aquatic Organisms Molecular Structure Animals Depsipeptides Covering 2010-April 2024There have been tremendous new discoveries and developments since 2010 in anticancer research based on marine cyanobacteria. Marine cyanobacteria are prolific sources of anticancer natural products, including the tubulin agents dolastatins 10 and 15 which were originally isolated from a mollusk that feeds on cyanobacteria. Decades of research have culminated in the approval of six antibody-drug conjugates (ADCs) and many ongoing clinical trials. Antibody conjugation has been enabling for several natural products, particularly cyanobacterial cytotoxins. Targeting tubulin dynamics has been a major strategy, leading to the discovery of the gatorbulin scaffold, acting on a new pharmacological site. Cyanobacterial compounds with different mechanisms of action (MOA), targeting novel or validated targets in a range of organelles, also show promise as anticancer agents. Important advances include the development of compounds with novel MOA, including apratoxin and coibamide A analogues, modulating cotranslational translocation at the level of Sec61 in the endoplasmic reticulum, largazole and santacruzamate A targeting class I histone deacetylases, and proteasome inhibitors based on carmaphycins, resembling the approved drug carfilzomib. The pipeline extends with SERCA inhibitors, mitochondrial cytotoxins and membrane-targeting agents, which have not yet advanced clinically since the biology is less understood and selectivity concerns remain to be addressed. In addition, efforts have also focused on the identification of chemosensitizing and antimetastatic agents. The review covers the state of current knowledge of marine cyanobacteria as anticancer agents with a focus on the mechanism, target identification and potential for drug development. We highlight the importance of solving the supply problem through chemical synthesis as well as illuminating the biological activity and in-depth mechanistic studies to increase the value of cyanobacterial natural products to catalyze their development. |
| title | Progress in the discovery and development of anticancer agents from marine cyanobacteria. |
| topic | Cyanobacteria Antineoplastic Agents Humans Biological Products Drug Discovery Aquatic Organisms Molecular Structure Animals Depsipeptides |
| url | https://pubmed.ncbi.nlm.nih.gov/39620500/ |